Full Text View
Tabular View
No Study Results Posted
Related Studies
Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators
This study is ongoing, but not recruiting participants.
First Received: August 16, 2007   No Changes Posted
Sponsor: Ethicon, Inc.
Information provided by: Ethicon, Inc.
ClinicalTrials.gov Identifier: NCT00518102
  Purpose

The purpose of this retrospective study is to compare the risk of cancers in people who have used becaplermin to that of people with similar characteristics and health issues who have not used becaplermin


Condition Phase
Cancer
Foot Ulcer, Diabetic
Diabetic Foot
Foot Ulcer
Neoplasms
Phase IV

Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Retrospective Study
Official Title: A Cohort Study of the RIsk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators

Resource links provided by NLM:


Further study details as provided by Ethicon, Inc.:

Estimated Enrollment: 2000
Study Start Date: January 1998
Detailed Description:

This is an observational (review of records), retrospective (research activity that is performed after the events under the study have occurred) study where data was collected from a medical claims database. The objective of this study was to determine the incidence of cancer among becaplermin users relative to non-users. Adults who were treated with becaplermin between January 1, 2003 and June 30, 2003 were identified in a health insurance claims database. Another group of adults with similar characteristics but who had not been treated with becaplermin were also identified in the database. The medical records of the two groups were followed for an average of 20 months and any diagnosis of cancer was identified and categorized based on type and location of the cancer. Any incidenceof death from cancer was also identified.

This retrospective study did not involve the use of any investigational drug and did not mandate the treatment regimen that the patients received.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients treated with becaplermin in the medical claims database and subsequently patients similar to them for a matched control group

Exclusion Criteria:

  • Patients not treated with becaplermin
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00518102

Sponsors and Collaborators
Ethicon, Inc.
Investigators
Study Director: Ethicon, Inc. Clinical Trial Ethicon, Inc.
  More Information

No publications provided

Study ID Numbers: CR012010
Study First Received: August 16, 2007
Last Updated: August 16, 2007
ClinicalTrials.gov Identifier: NCT00518102     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Ethicon, Inc.:
neoplasms
Regranex
cancer
foot ulcer
PDGF-BB
diabetic foot ulcer
Becaplermin

Additional relevant MeSH terms:
Foot Ulcer
Diabetic Neuropathies
Skin Diseases
Growth Substances
Ulcer
Physiological Effects of Drugs
Diabetes Mellitus
Vascular Diseases
Endocrine System Diseases
Foot Diseases
Pharmacologic Actions
Diabetic Angiopathies
Neoplasms
Pathologic Processes
Platelet-derived growth factor BB
Angiogenesis Inducing Agents
Cardiovascular Diseases
Angiogenesis Modulating Agents
Skin Ulcer
Diabetes Complications
Diabetic Foot
Leg Ulcer

ClinicalTrials.gov processed this record on November 27, 2009